Drug Farm Completes First Closing of USD 55 Million Series D Financing to Advance Clinical and Preclinical R&D Pipelines

Drug Farm has successfully completed the first closing of its Series D financing round of USD 55 million. This round was jointly led by Shanghai Pudong Leading Area Investment Center and Shanghai Puxing Collaborative Private Equity Fund Partnership, with follow-on participation from Zhikai Capital Fuzhou Xinhe Fund, Shenzhen Luohu Donghai Ruizhi Pharmaceutical Industry Investment Partnership, and Keyuan Pharmaceutical. Existing investors including BVCF, YD Capital, Jiashan State-owned Assets Investment, Detong Capital, Weidu Capital, and Biometas also continued their investments. HaoYue Capital served as the exclusive financial advisor for this transaction.

The proceeds from this financing round will be used to continue advancing the company's clinical and preclinical-stage research and development pipelines, accelerate global clinical development programs, strengthen regulatory and registration efforts in key markets, and further expand the company's research and development capabilities.

Dr. Xu Tian, founder and chairman of Drug Farm, stated: "The successful completion of this financing round is an important milestone on Drug Farm's path to fulfilling its mission of 'developing first-in-class drugs for the world.' We are pleased to welcome new investors and are grateful for the continued support from our long-term shareholders, which fully demonstrates their confidence in the company's scientific innovation capabilities, development strategy, and long-term vision. We believe that this financing will enable Drug Farm to create significant value for patients, partners, and shareholders in the future."

Dr. Henri Lichenstein, Chief Executive Officer of Drug Farm, added: "We are delighted to have completed this financing round and sincerely thank our investors for their continued trust and support. We are proud that DF-003 is one of the first first-in-class drugs developed with artificial intelligence to advance into Phase III clinical trials. This investment will provide additional resources to advance DF-003 through a pivotal trial in patients with ROSAH syndrome and to achieve clinical proof-of-concept in atherosclerotic cardiovascular disease. The proceeds will also be used to continue advancing the clinical development of DF-006 in patients with hepatitis B."

Dr. Xu Cong, Chief Operating Officer of Drug Farm, stated: "Leveraging our proprietary platforms IDInVivo+ and MedChem5, which integrate genetics and artificial intelligence, we continue to discover and validate novel drug targets and rapidly advance multiple first-in-class drug candidates into clinical development. This financing will help us bring more breakthrough therapies to patients with unmet needs in metabolic and autoimmune diseases."

Ms. Wu Xiaokun, Partner at HaoYue Capital, stated: "It is a great honor to serve as the long-term partner and exclusive financial advisor for Drug Farm in this financing round. Throughout the company's development, we have witnessed Drug Farm's commitment to deep source innovation through its proprietary IDInVivo+ and MedChem5 platforms, continuously uncovering novel drug targets and delivering consistent value across its core pipeline. DF-003 has become one of the world's first first-in-class drugs developed with artificial intelligence to advance into Phase III clinical trials, while also demonstrating broad therapeutic potential in cardiovascular and renal diseases. The hepatitis B pipeline asset DF-006 has shown promising clinical data. 

The company continues to achieve breakthrough progress in major unmet medical needs including rare diseases, metabolic diseases, and chronic liver diseases. This financing round fully demonstrates the capital market's strong confidence in the company's core technology platforms, first-in-class drug pipeline, and long-term development strategy. HaoYue Capital will continue to serve as a bridge between the capital market and the biopharmaceutical industry, providing comprehensive capital services to Drug Farm, supporting the company in continuously unlocking its innovation value, and achieving sustained, high-quality development on the global biotechnology innovation landscape."

Drug Farm is a biotechnology company dedicated to developing first-in-class drugs, committed to advancing innovative therapies for ROSAH syndrome, cardiovascular and renal diseases, hepatitis B, and metabolic diseases. The company's proprietary IDInVivo+ and MedChem5 platforms integrate genetics with artificial intelligence technologies to discover and validate novel drug targets directly within living systems. Drug Farm is advancing multiple first-in-class drug candidates into clinical development.

DF-003 is a first-in-class drug independently developed through Drug Farm's MedChem5 artificial intelligence medicinal chemistry platform, which inhibits the activity of ALPK1 and its pathogenic mutants. In an ongoing Phase Ib clinical study, DF-003 has demonstrated evidence of clinical improvement across multiple symptoms of ROSAH syndrome. DF-003 is one of the first first-in-class drugs developed with artificial intelligence to advance into Phase III clinical trials. Based on efficacy observed in preclinical models, DF-003 also holds therapeutic potential in cardiovascular and renal diseases. DF-003 has received multiple designations from the United States Food and Drug Administration, including Fast Track, Orphan Drug, Rare Pediatric Disease, and Rare Disease Evidence Principles. The discovery of DF-003 has been published in Nature Communications.

DF-006 is a first-in-class oral ALPK1 agonist immunomodulatory drug independently developed by Drug Farm, which effectively activates liver-localized innate immunity. DF-006 has successfully completed single-ascending-dose and multiple-ascending-dose evaluations in healthy volunteers, as well as multiple-ascending-dose evaluations in virologically suppressed HBeAg-negative chronic hepatitis B patients, with encouraging anti-HBV activity observed. The discovery of DF-006 has been published in Hepatology. Drug Farm has entered into a clinical collaboration with Xiamen Amoytop Biotech Co., Ltd. to jointly advance DF-006 for the treatment of hepatitis B and hepatocellular carcinoma.